Committee publication · Correspondence · 29 June 2026

Letter from the Chief Operating Officer of the Civil Service and Permanent Secretary at the Cabinet Office relating to Compensation scheme oral evidence follow-up, 18 June 2026

From: Public Accounts Committee

Inquiry: Government compensation schemes: update

Summary

Catherine Little, Civil Service Chief Operating Officer, responds to PAC's oral evidence follow-up regarding why the Government is not pursuing redress from American pharmaceutical companies in the infected blood scandal. She explains that the Infected Blood Inquiry found many companies no longer exist as separate legal entities due to dissolutions, liquidations, or acquisitions, making it legally inappropriate to hold current corporate successors responsible for historical conduct.

Key findings

  • The Infected Blood Inquiry's Volume 4 report identified that pharmaceutical companies involved in the scandal have been dissolved, liquidated, or absorbed through takeovers, with no separate legal identity to pursue
  • The Inquiry concluded it would be inappropriate to hold present-day corporate entities responsible for actions taken by different corporate entities decades ago, despite name commonality
  • Government's approach to redress is informed by the Inquiry's legal analysis on corporate liability and the moral imperative to provide compensation to victims
  • The previous Government accepted the moral case for compensation in 2022; the current Government emphasises the Infected Blood Compensation Scheme as providing closure and upholding justice

Tone

Procedural

Topics

public-compensationinfected-blood-scandalaccountabilitygovernment-redress

Key actors

Catherine Little, Sir Geoffrey, Public Accounts Committee, Infected Blood Inquiry, Cabinet Office, Previous Government, American pharmaceutical companies

Notable line

… it would be inappropriate simply by reason of a commonality of label to hold them (as they exist now) responsible for what was done by what were different corporate entities some considerable time ago." The Inquiry's views …

Key Quotes

… it would be inappropriate simply by reason of a commonality of label to hold them (as they exist now) responsible for what was done by what were different corporate entities some considerable time ago." The Inquiry's views …
Infected Blood Inquiry (quoted by Catherine Little) · explaining why pharmaceutical companies cannot be held liable
… the 'failure to bring the true facts to life has come partly from the inertia of groupthink; but partly, it must be recognised from instinctive defensiveness, to save face and to save expense.
Infected Blood Inquiry (quoted by Catherine Little) · describing systemic failures in addressing the scandal
… it is absolutely fundamental that those impacted by this scandal have access to redress, not least to uphold justice and fairness in our society
Catherine Little · stating the Government's commitment to compensation
View original document →

Source · parliament.uk record ↗